| Name | Title | Contact Details |
|---|
Today, with literally thousands of sports apps, medical apps, nutritional apps and of course doctors` offices and hospitals offering online access to your medical records the chances of anyone checking all their vitals, nutritional intake etc. is close to nil… Why? Way too much data!! WoMBA takes all your data sources and aggregates it under one platform. Aggregated data allows you to see a full picture of your health and gives you a full profile of your E-DNA. Not only does utilizing WoMBA give you easy access to your collected data but many insurance companies will give you a discount for using services such as WoMBA and last but not list, if not the most important, WoMBA can save your life.
Medical Supply Corporation is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthsense is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bodycad helps healthcare professionals and patients achieve their common pursuit of perfection by actualizing personalized orthopedic restorations. Bodycad enables orthopedic surgeons to create a personalized restoration based on the anatomical specifications of their patient using the company`s proprietary Personalized Restoration Software. Surgeons can quickly and efficiently step through the Bodycad PREP (Personalized Restoration Evaluation Process) to scan their patients and create a specific design plan, approve the design, and perform the restoration. The company is committed to providing high-touch education, training and service, including access to Bodycad PREP Techs to help assure surgical success. Bodycad is transforming the current standard of orthopedic implants to help surgeons and patients achieve their mutual goal of a perfect personalized restoration.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.